Live Breaking News & Updates on Double voting rights

Stay informed with the latest breaking news from Double voting rights on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Double voting rights and stay connected to the pulse of your community

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

31.05.2022 - MONT-SAINT-GUIBERT, Belgium, May 31, 2022 (GLOBE NEWSWIRE) - Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and the development of Chimeric Antigen Receptor T cell (CAR ...

Mont-saint-guibert , Waals-gewest , Belgium , New-york , United-states , Walloon-region , Filippo-petti , Double-voting-rights , Chief-executive-officer , Media-contacts ,

Celyad Oncology SA: Celyad: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology SA: Celyad: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
1,802,756
created following the exercise of the attributed warrants
1,802,756
Warrants)
19.175.937
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO):
investors@celyad.com
investors@celyad.com
About Celyad Oncology
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit

Mont-saint-guibert , Waals-gewest , Belgium , New-york , United-states , Walloon-region , Paris , France-general , France , Belgian , Sara-zelkovic , Filippo-petti